GGrantIndex
← Search

GASTROINTESTINAL CANCER

$78,870U10FY2002CANIH

Mayo Clinic Coll Of Medicine, Rochester, Rochester MN

Investigators

Linked publications, trials & patents

Paper 39055377Paper 37539667Paper 36050448Paper 35859079Paper 34804634Paper 33154022Paper 32923882Paper 32504284Paper 31802506Paper 31213748Paper 30775161Paper 29848457Paper 29649081Paper 29530935Paper 29313954Paper 29164377Paper 29138761Paper 29044496Paper 28939223Paper 28921241Paper 28917648Paper 28786105Paper 28700816Paper 28691116Paper 28691057Paper 28687377Paper 28649983Paper 28646344Paper 28620884Paper 28533226Paper 28493308Paper 28402581Paper 28384065Paper 28375706Paper 28323331Paper 28280603Paper 28262692Paper 28239505Paper 28089762Paper 28006055Paper 27943153Paper 27881709Paper 27590208Paper 27534963Paper 27478689Paper 27468630Paper 27458945Paper 27374464Paper 27365012Paper 27302508Paper 27197192Paper 27098150Paper 27075674Paper 27060850Trial NCT01648348Trial NCT01369849Trial NCT01086605Trial NCT00869401Trial NCT00826540Trial NCT00738881Trial NCT00731731Trial NCT00699491Trial NCT00684983Trial NCT00641706Trial NCT00528645Trial NCT00459862Trial NCT00398112Trial NCT00369655Trial NCT00329719Trial NCT00321724Trial NCT00316849Trial NCT00255762Trial NCT00238394Trial NCT00238303Trial NCT00110084Trial NCT00109967Trial NCT00098540Trial NCT00096434Trial NCT00096070Trial NCT00093756Trial NCT00079274Trial NCT00079235Trial NCT00052949Trial NCT00052689Trial NCT00049127Trial NCT00039494Trial NCT00033267Trial NCT00027612Trial NCT00026234Trial NCT00026182Trial NCT00016328Trial NCT00015990Trial NCT00015821Trial NCT00014170Trial NCT00006226Trial NCT00005970Trial NCT00005036Trial NCT00003869Trial NCT00003140Patent 8507518

Abstract

The NCCTG Gastrointestinal (GI) Cancer Program brings together specialists from all oncology disciplines with the following goals: 1. To improve cure rates when possible or extend survival/improve patient quality of life. a) Initiation/leadership of GI Intergroup/NCCTG phase III clinical trials. b) Participation in GI Intergroup trials led by other oncology groups. c) Rapid initiation/completion of Pilot Studies and Phase II trials, based on the most promising GI cancer treatment strategies developed in the Mayo Clinic Phase I program or elsewhere in collaboration with the NCCTG Novel Therapeutics Committee. This strategy manifests itself in the performance of targeted research studies across the eight primary GI tract sites. d) Integration of multiple modalities (surgery, radiation, and medical oncology) and participation of the appropriate modality committees in trial design and conduct. 2. To devise therapies that an be administered in proximity to the patient's home, with referral to specialized centers when approprite. a) By forging a research-driven partnership between the research and community bases. b) By conducting education symposia based in and around NCCTG meetings. 3) To further the understanding of tumor biology and host response through the investigation of prognostic determinants, factors influencing disease progression, and individual responses to chemotherapy (i.e. translational research). a) Interaction with Mayo Clinic researchers with expertise in correlative science. b) Collaboration with laboratory-based investigators elsewhere. 4. To utilize the extensive NCCTG database in completed studies to answer questions arising in clinical practice, from analyses of prospective trials, or from the literature. 5. To monitor and improve patient quality of life (QOL) and the tools to assess QOL. 6. To advance the field of clinical trials research by design of new trial paradigms and systems for optimal data collection in response to issues arising from our studies. 7. To entice involvement from diverse members of the multi-disciplinary oncology team in collaborations dedicated to extending the horizons of cancer care. This application will focus on the past, present, and projected future of the NCCTG GI Program based upon our accomplishments during the last grant period. We will delineate specific programmatic approaches that define the NCCTG GI Program based on the philosophical principles noted above. We will concentrate on our accomplishments in the prior grant period (present), and project the themes and outline the new initiatives that we hope will define our program in the next grant period (future).

View original record on NIH RePORTER →